Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Amortization of Deferred Charges (2022 - 2026)

HeartSciences (HSCS) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $263880.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortization of Deferred Charges changed N/A year-over-year to $263880.0, compared with a TTM value of $593730.0 through Oct 2025, changed N/A, and an annual FY2025 reading of $285870.0, up 175.95% over the prior year.
  • Amortization of Deferred Charges was $263880.0 for Q4 2025 at HeartSciences, up from $109950.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $263880.0 in Q4 2025 and bottomed at $20719.0 in Q1 2024.
  • Average Amortization of Deferred Charges over 3 years is $114085.0, with a median of $109950.0 recorded in 2025.
  • Peak annual rise in Amortization of Deferred Charges hit 430.67% in 2025, while the deepest fall reached 430.67% in 2025.
  • Year by year, Amortization of Deferred Charges stood at $61381.0 in 2022, then tumbled by 66.25% to $20719.0 in 2024, then soared by 1173.61% to $263880.0 in 2025.
  • Business Quant data shows Amortization of Deferred Charges for HSCS at $263880.0 in Q4 2025, $109950.0 in Q3 2025, and $109950.0 in Q2 2025.